Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level

Clinical Cancer Research

Volumn 6, Issue 12, 2000, Pages 4733-4738

  Ando, Masahiko ^a,d   Minami, Hironobu ^f   Ando, Yuichi ^d   Saka, Hideo ^b   Sakai, Shuzo ^a   Yamamoto, Masashi ^c   Sasaki, Yasutsuna ^f   Shimokata, Kaoru ^e   Hasegawa, Yoshinori ^d  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c NAGOYA EKISAIKAI HOSPITAL   (Japan)

^d First Dept of Internal Medicine   (Japan)

^e NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CREATININE;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE CALCULATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOLID TUMOR; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BIAS (EPIDEMIOLOGY); CARBOPLATIN; CREATININE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PEROXIDASE; TIME FACTORS;

EID: 0034489195     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin
2. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer
3. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
4. Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer
5. Multi-institutional Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer
6. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer
7. Clinical evaluation of kidney function - Glomerular function
8. Limitations of creatinine as a filtration marker in glomerulopathic patients
9. Laboratory assessment of renal disease: Clearance, urinalysis, and renal biopsy
10. Simple, rapid, kinetic method for serum creatinine measurement
11. Multicentre evaluation of an enzymatic method for creatinine determination using a sensitive colour reagent
12. Evaluation of an enzymatic method for determining creatinine in plasma
13. Serum creatinine as an index of renal function: New insights into old concepts
14. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel
15. Prediction equation for glomerular filtration rate
16. Laboratory evaluation of renal function
17. Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule
18. Adjustment of creatinine clearance improves accuracy of Calvert’s formula for carboplatin dosing
19. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: A comparison of the performance of three formulae
20. Prediction of carboplatin clearance from standard morphological and biological patient characteristics
21. Prediction of creatinine clearance from serum creatinine
22. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma
23. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel
24. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers
25. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose
26. Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry
27. Some suggestions for measuring predictive performance
28. A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer
29. Clinical pharmacokinetics and dose optimisation of carboplatin
30. Creatinine clearance: Enzymatic vs Jaffé determinations of creatinine in plasma and urine
31. Assessment of renal function by serum creatinine and creatinine clearance: Glomerular filtration rate estimated by four procedures
32. Re: Prediction of carboplatin clearance from standard morphological and biological patient characteristics
33. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin
34. Re: Prediction of carboplatin clearance from standard morphological and biological patient characteristics